
    
      This is a global, multicenter open-label, single-arm, Phase 2 study of the PI3KÎ´ inhibitor
      Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone
      lymphoma after failure of at least 2 prior lines of systemic therapy which must have included
      an anti-CD20 antibody and chemotherapy with an alkylating agent or a purine analogue.

      Approximately 180 subjects will be enrolled and treated with Zandelisib (ME-401) on the
      intermittent schedule.
    
  